Opinion|Videos|October 25, 2024
Key Takeaways on Recent Advances in SCLC
Key Takeaways
- Tarlatamab represents a significant advancement in SCLC treatment, offering new hope beyond first-line therapies.
- Clinical trials are investigating novel immunotherapies and targeted treatments, showing promise for SCLC management.
Panelists discuss how the landscape of small cell lung cancer (SCLC) treatment is rapidly evolving, highlighting key advances in immunotherapy, targeted treatments like tarlatamab, and ongoing research efforts, while emphasizing the importance of early diagnosis, appropriate staging, and personalized treatment approaches to improve patient outcomes and quality of life.
Advertisement
Episodes in this series
We’ve discussed first-line therapies and a newly approved therapy tarlatamab.
- Beyond first-line therapies, what options exist for patients, and what clinical trials are you excited about?
- What are some of the therapies being researched for small cell lung cancer (SCLC) that you are excited about?
How do you see the management of SCLC evolving in the future?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success
2
CANN Responds to HRSA's Revised 340B Rebate Model Pilot
3
Setting Treatment Goals in RA: Remission, Joint Damage, and Systemic Risk
4
Predicting GLP-1 Discontinuation From Pharmacy Claims
5